![Eli Lilly and Company / Dipeptidyl peptidase-4 inhibitor / Novo Nordisk / Sanofi / Technology / Pharmaceutics / Pharmaceutical Research and Manufacturers of America / Pharmaceutical industry in the United Kingdom / Pharmaceutical industry / Healthcare in India / Pharmaceutical industry in India Eli Lilly and Company / Dipeptidyl peptidase-4 inhibitor / Novo Nordisk / Sanofi / Technology / Pharmaceutics / Pharmaceutical Research and Manufacturers of America / Pharmaceutical industry in the United Kingdom / Pharmaceutical industry / Healthcare in India / Pharmaceutical industry in India](https://www.pdfsearch.io/img/3f756c1f7bca6ade1b128ff47392b065.jpg) Date: 2013-04-24 07:17:09Eli Lilly and Company Dipeptidyl peptidase-4 inhibitor Novo Nordisk Sanofi Technology Pharmaceutics Pharmaceutical Research and Manufacturers of America Pharmaceutical industry in the United Kingdom Pharmaceutical industry Healthcare in India Pharmaceutical industry in India | | CANADIAN DIABETES ASSOCIATION 2013 CLINICAL PRACTICE GUIDELINES FOR THE PREVENTION AND MANAGEMENT OF DIABETES IN CANADA DUALITY OF INTEREST DISCLOSURES EXECUTIVE, STEERING & EXPERT COMMITTEESAdd to Reading ListSource URL: guidelines.diabetes.caDownload Document from Source Website File Size: 178,46 KBShare Document on Facebook
|